Neosar

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1997-2017
024619972017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2003
Review
2003
In patients with advanced breast cancer, treatment with paclitaxel and doxorubicin has been shown to produce impressive overall… (More)
Is this relevant?
Review
2001
Review
2001
Recently initiated is a phase III randomized trial (MA.21 trial) of adjuvant chemotherapy for node-positive and high-risk node… (More)
Is this relevant?
Review
2000
Review
2000
Pentostatin (Nipent) has demonstrated significant activity as a single agent in patients with low-grade B- and T-cell lymphomas… (More)
Is this relevant?
1998
1998
This study evaluated the safety and feasibility of the combination of paclitaxel (Taxol) and epirubicin, the 4'-epimer of… (More)
Is this relevant?
1997
1997
Optimal management of locally advanced breast cancer (stage III) generally includes a combination of primary chemotherapy… (More)
Is this relevant?
1997
1997
Preliminary results from phase I trials suggest that the use of docetaxel (Taxotere) and doxorubicin (Adriamycin) is a well… (More)
Is this relevant?
1997
1997
Protocol B-27, conducted by the National Surgical Adjuvant Breast and Bowel Project (NSABP), is a phase III, randomized trial… (More)
Is this relevant?
1997
1997
Preclinical studies show that docetaxel (Taxotere) and cyclophosphamide (Cytoxan, Neosar) are synergistic against MA 13/C mammary… (More)
Is this relevant?
1997
1997
This trial was designed to determine the recommended maximum tolerated dose (MTD), toxicity, pharmacokinetics, and efficacy of… (More)
Is this relevant?
Review
1997
Review
1997
Clinical trials to develop paclitaxel (Taxol)-containing combinations started in 1992 with several approaches to combine… (More)
Is this relevant?